Horizon Pharma has gone hostile with an all-stock offer for Depomed valued at about $2.1 billion after its target rejected friendly overtures to talk about a deal.
The Dublin-based company said Tuesday that it will take an offer of $29.25 of its stock for each Depomed share directly to that companyâs shareholders. The tax-free bid represents about a 42 percent premium to Depomedâs closing price Monday.
Horizon said it has been trying to discuss a deal with Depomed Inc. since March, but that comp...
Share this post
← Back to Utah